Antibe Therapeutics Unveils Lead Indication for Second Pipeline Drug

Ontario Industry Updates
Written By Guest User

Antibe Therapeutics announced the lead indication for its second pipeline drug, ATB-352, a potent and non-addictive analgesic for the treatment of severe pain.

Click here to learn more

Guest User
Previous

FACIT Portfolio Announces $750M Follow-On Financing
Next

Why Ontario needs a network of Early Adopter Health Organizations: Biotechnology Focus